Parexel has expanded its capabilities in patient safety by acquiring Vitrana, a move that enhances their integrated pharmacovigilance (PV) solutions through advanced AI and automation technologies.
This acquisition allows Parexel to offer a comprehensive PV solution that is adaptable to various safety databases, thereby improving accuracy and compliance in a complex regulatory environment. As a result, Parexel aims to streamline operations and respond to the industry's growing need for unified service models.
Sanjay Vyas, a key executive at Parexel, emphasized that the integration will simplify workflows and enable professionals to focus on product and patient safety, ultimately driving operational efficiencies. The new model is designed to benefit all stages of the clinical trial lifecycle, promising quicker issue resolution and enhanced vendor management.
Mohit Gupta from Vitrana noted that the partnership will allow for the global scaling of their technology, improving overall efficiency and compliance in pharmacovigilance. The integration will be gradual, ensuring a smooth transition for existing customers while maintaining commitments to product development and service delivery.
This strategic move not only positions Parexel as a leader in AI-driven patient safety solutions but also reflects the broader trend in the life sciences sector towards integrated, technology-driven services that enhance patient outcomes and regulatory compliance.